

Legal & General
Global Health and Pharmaceuticals Index Trust

Annual Manager's Report
for the year ended
7 January 2019



Contents

	Page Number
Manager's Investment Report*	2
Authorised Status*	5
Directors' Statement	5
Statement of the Manager's Responsibilities	6
Statement of the Trustee's Responsibilities	7
Report of the Trustee	8
Portfolio Statement*	9
Independent Auditor's Report	15
Statement of Total Return	18
Statement of Change in Net Assets attributable to Unitholders	18
Balance Sheet	19
Notes to the Financial Statements	20
Distribution Table	33
Trust Information*	34
Risk and Reward Profile (unaudited)*	41
General Information (unaudited)*	42

* These collectively comprise the Authorised Fund Manager's Report.

Manager's Investment Report

Investment Objective and Policy

The objective of the Trust is to secure capital growth from a portfolio of securities representing companies engaged in Health, Pharmaceuticals and Biotechnology.

Securities representing all such companies in the FTSE World Index will be held with weightings generally proportionate to their market capitalisation.

From time to time, non-Index constituents may be held as a result of a corporate action and these holdings will be sold or transferred as soon as reasonably practical.

The Trust may hold derivatives for the purpose of Efficient Portfolio Management.

Manager's Investment Report

During the year under review, the bid price of the Trust's R-Class distribution units rose by 5.57%. FTSE, the Index compiler, calculates the benchmark Index at the end of the business day using closing prices, whereas the Trust is valued using prevailing prices at 3pm. Therefore, for tracking purposes the Trust has been revalued using closing prices and foreign exchange rates. On this basis, over the review year, the Trust rose by 5.06%, on a capital only basis compared with the FTSE World Health and Pharmaceutical Index rise of 4.99%(Source: Rimes), producing a tracking difference of +0.07%.

Past performance is not a guide to future performance.

The value of investments and any income from them may go down as well as up.

Exchange rate changes may cause the value of any overseas investments to rise or fall.

The FTSE World Index is calculated by FTSE International Limited ("FTSE"). FTSE does not sponsor, endorse or promote this product.

All copyright in the Index values and constituent list belongs to FTSE.

Legal & General has obtained full licence from FTSE to use such copyright in the creation of this product.

"FTSE™", "FT-SE®" and "Footsie®" are trademarks of the London Stock Exchange Plc and The Financial Times Limited and are used by FTSE International Limited ("FTSE") under license.

Market/Economic Review

International equities fell sharply during December 2018, and recorded their worst year since the global financial crisis. A combination of factors ensured the year ended on a disappointing note. Concerns that the Federal Reserve was raising US interest rates too quickly, the risk of a prolonged federal government shutdown in the US, the ongoing US-China trade dispute and weaker global economic indicators all combined to trigger widespread risk aversion amongst investors. In contrast with previous months, the US underperformed international indices with energy stocks and technology amongst the weakest sectors. The oil price fell back to a 15-month low in mid-December 2018, driven by concerns over a supply glut, as shale production in the US continues to grow rapidly, while OPEC producers appear unwilling to cut production. In the IT sector, microchip maker Nvidia's struggle continued in December 2018, with the shares halving in value over the final quarter of 2018, while concerns over a slowdown in iPhone sales drove Apple shares lower. Weaker economic indicators in Europe and Japan added to investors' concerns in these markets, with official data highlighting the Japanese economy recorded its steepest contraction since the second quarter of 2014, during the three months to September. However, both Asia Pacific excluding Japan and emerging markets proved relatively resilient with losses much smaller than those recorded in developed markets.

Manager's Investment Report continued

After largely following the moves in broader global equities over the first half of 2018, the healthcare sector subsequently outperformed global equities by a substantial margin. Impressive earnings updates, boosted by the success of new products that offset worries over generic competition, lifted valuations. The sector's defensive earnings characteristics also supported returns during a volatile fourth quarter. Encouraging trading updates, particularly over the second half of 2018, boosted pharmaceuticals such as Merck, Eli Lilly, Abbott Laboratories and Pfizer. However, personal care products giant Johnson & Johnson lost ground amid safety-related allegations related to its Baby Powder talcum powder dating back several decades.

Trust Review

At the end of the year under review, there were 93 companies in the FTSE World Index classified as Pharmaceuticals and Biotechnology, and a further 77 companies classified under the Health Care Equipment and Services sector. These sub sectors account for approximately 69% and 31% of the portfolio respectively.

The top 10 holdings in the portfolio are shown below. These represent approximately 40% of the Trust by market value and consist of the 10 largest Pharmaceutical companies in the world.

Johnson & Johnson (US)

Pfizer (US)

UnitedHealth Group (US)

Merck & Company (US)

Novartis (Switzerland)

Roche (Part Certified) (Switzerland)

AbbVie (US)

Amgen (US)

Medtronic (Ireland)

Abbott Laboratories (US)

The March quarterly Index review resulted in six additions of which Alnylam Pharmaceuticals and Teleflex (Both US) were the biggest. There were two deletions of which Patterson (US) was the biggest. There were a further 17 changes to the free share capital of constituents with the largest increase being Aspen Pharmacare (US) and the largest decrease being Novartis (Switzerland). Two-way Index turnover was 1.54%.

The June quarterly Index review resulted in no additions and two deletions: Getinge B and Arjo B (Both Sweden). There were 114 changes to the free share capital of constituents with the largest increase being Bayer (Germany) and the largest decrease being Amgen (US). Two-way Index turnover was 1.32%.

The September quarterly Index review resulted in 12 additions and two deletions, the largest being Hoya (Japan) and Waters Corp (US), respectively. There were 17 changes to the free share capital of constituents with the largest increases being Anthem (US), SillaJen (South Korea) and Terumo (Japan) and the largest decreases being AbbVie, Amgen and Merck & Company (All US). Two-way Index turnover was 3.82%.

Manager's Investment Report continued

The December quarterly Index review resulted in two additions and two deletions, the largest being Notre Dame Intermedica Participacoes (Brazil) and Express Scripts (US), respectively. There were 20 changes to the free share capital of constituents with the largest increases being Takeda Pharmaceutical, Cigna and Essilor International and the largest decreases being Merck & Company, Cardinal Health and Amgen (All US). Two-way Index turnover was 4.68%.

Outlook

Two countervailing forces have kept markets in a holding pattern recently: global economy and company earnings growth, and the ascent of populist economic policies. Trade wars continue to occupy markets' attention and although there has yet to be any major fall-out, our economists do anticipate some damage to growth over the next year, and have slightly revised down our economic growth (GDP) forecasts for both, US and China. The Federal Reserve has continued to raise US interest rates, likely to lead to a stronger Dollar over time.

The Trust remains well positioned to capture the performance of the Index.

Legal & General Investment Management Limited
(Investment Adviser)
22 January 2019

Authorised Status

Authorised Status


This Trust is an Authorised Unit Trust Scheme as defined in section 243 of the Financial Services and Markets Act 2000 and is a UCITS Retail Scheme within the meaning of the FCA Collective Investment Schemes sourcebook.

Directors' Statement

We hereby certify that this Manager's Report has been prepared in accordance with the requirements of the FCA Collective Investment Schemes sourcebook.



A. J. C. Craven
(Director)



L. W. Toms
(Director)

Legal & General (Unit Trust Managers) Limited
26 February 2019

Statement of Responsibilities

Statement of the Manager's Responsibilities

The Collective Investment Schemes sourcebook published by the FCA, ("the COLL Rules") require the Manager to prepare financial statements for each annual accounting period which give a true and fair view of the financial position of the Trust and of the net income and net gains or losses on the property of the Trust for the period.

In preparing the financial statements, the Manager is responsible for:

- selecting suitable accounting policies and then apply them consistently;
- making judgements and estimates that are reasonable and prudent;
- following UK accounting standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland;
- complying with the disclosure requirements of the Statement of Recommended Practice for UK Authorised Funds issued by the Investment Management Association in May 2014;
- keeping proper accounting records which enable it to demonstrate that the financial statements as prepared comply with the above requirements;
- assessing the Trust's ability to continue as a going concern, disclosing, as applicable, matters related to going concern;
- using the going concern basis of accounting unless they either intend to liquidate the Trust or to cease operations, or have no realistic alternative but to do so;
- such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error; and
- taking reasonable steps for the prevention and detection of fraud and irregularities.

The Manager is responsible for the management of the Trust in accordance with its Trust Deed, the Prospectus and the COLL Rules.

Statement of Responsibilities continued

Statement of the Trustee's Responsibilities

The Depositary in its capacity as Trustee of Legal & General Global Health and Pharmaceuticals Index Trust must ensure that the Trust is managed in accordance with the Financial Conduct Authority's Collective Investment Schemes Sourcebook, the Financial Services and Markets Act 2000, as amended, (together "the Regulations"), the Trust Deed and Prospectus (together "the Scheme documents") as detailed below.

The Depositary must in the context of its role act honestly, fairly, professionally, independently and in the interests of the Trust and its investors.

The Depositary is responsible for the safekeeping of all custodial assets and maintaining a record of all other assets of the Trust in accordance with the Regulations.

The Depositary must ensure that:

- the Trust's cash flows are properly monitored and that cash of the Trust is booked in cash accounts in accordance with the Regulations;
- the sale, issue, repurchase, redemption and cancellation of units are carried out in accordance with the Regulations;
- the value of units of the Trust are calculated in accordance with the Regulations;
- any consideration relating to transactions in the Trust's assets is remitted to the Trust within the usual time limits;
- the Trust's income is applied in accordance with the Regulations; and
- the instructions of the Authorised Fund Manager ("the AFM"), which is the UCITS Management Company, are carried out (unless they conflict with the Regulations).

Report of the Trustee

Report of the Trustee to the Unitholders of the Legal & General Global Health and Pharmaceuticals Index Trust ("the Trust") for the year ended 7 January 2019

The Depositary also has a duty to take reasonable care to ensure that the Trust is managed in accordance with the Regulations and the Scheme documents of the Trust in relation to the investment and borrowing powers applicable to the Trust.

Having carried out such procedures as we considered necessary to discharge our responsibilities as Depositary of the Trust, it is our opinion, based on the information available to us and the explanations provided, that, in all material respects the Trust, acting through the AFM:

- (i) has carried out the issue, sale, redemption and cancellation, and calculation of the price of the Trust's units and the application of the Trust's income in accordance with the Regulations and the Scheme documents of the Trust; and
- (ii) has observed the investment and borrowing powers and restrictions applicable to the Trust in accordance with the Regulations and the Scheme documents of the Trust.

Northern Trust Global Services SE
UK Trustee and Depositary Services
26 February 2019

Portfolio Statement

Portfolio Statement as at 7 January 2019

All investments are in ordinary shares unless otherwise stated. The percentages in brackets show the equivalent holdings at 7 January 2018.

Holding/ Nominal Value	Investment	Market Value £	% of Net Assets
UNITED KINGDOM — 4.64% (4.31%)			
156,174	AstraZeneca	9,395,428	2.08
177,858	ConvaTec Group	250,424	0.06
600,500	GlaxoSmithKline	9,061,545	2.00
19,283	Hikma Pharmaceuticals	328,679	0.07
47,368	Mediclinic International	148,072	0.03
10,537	NMC Health	295,247	0.07
106,114	Smith & Nephew	1,514,777	0.33
		20,994,172	4.64
IRELAND — 3.92% (4.25%)			
18,455	Alkermes	432,672	0.09
42,139	Allergan	4,678,520	1.03
7,053	Jazz Pharmaceuticals	707,011	0.16
165,798	Medtronic	11,427,723	2.52
15,638	Perrigo	530,975	0.12
		17,776,901	3.92
CHANNEL ISLANDS — 1.12% (0.98%)			
5,285	Shire ADR	741,116	0.16
92,422	SHIRE	4,334,592	0.96
		5,075,708	1.12
CONTINENTAL EUROPE — 19.45% (20.99%)			
Belgium — 0.21% (0.20%)			
14,456	UCB	924,234	0.21
Denmark — 2.92% (3.02%)			
20,765	Ambu	412,013	0.09
11,869	Chr. Hansen	859,558	0.19
16,040	Coloplast 'B'	1,185,142	0.26
7,198	Genmab	943,776	0.21
16,260	GN Store Nord	518,234	0.11
7,218	H. Lundbeck	250,435	0.06
209,318	Novo Nordisk	7,875,032	1.74
25,079	Novozymes 'B'	880,388	0.19
12,827	William Demant	300,140	0.07
		13,224,718	2.92
Finland — 0.08% (0.08%)			
12,456	Orion	361,964	0.08
France — 3.03% (2.97%)			
5,017	BioMérieux	257,093	0.06
35,771	Essilor International	3,552,158	0.78
4,193	Ipsen	424,655	0.09
5,426	Orpea	434,267	0.10

Portfolio Statement continued

Holding/ Nominal Value	Investment	Market Value £	% of Net Assets
	France — (cont.)		
133,605	Sanofi	8,853,686	1.95
2,808	Sartorius Stedim Biotech	218,109	0.05
		13,739,968	3.03
	Germany — 2.65% (3.73%)		
115,008	Bayer	6,580,912	1.45
4,446	Carl Zeiss Meditec	289,279	0.07
50,355	Fresenius	1,979,819	0.44
26,180	Fresenius Medical Care	1,374,000	0.30
15,933	Merck	1,276,906	0.28
15,808	Siemens Healthineers	513,849	0.11
		12,014,765	2.65
	Hungary — 0.06% (0.08%)		
16,755	Gedeon Richter	265,354	0.06
	Italy — 0.11% (0.09%)		
2,764	Diasorin	184,057	0.04
11,847	Recordati	319,387	0.07
		503,444	0.11
	Luxembourg — 0.09% (0.13%)		
1,359	Eurofins Scientific	403,942	0.09
	Netherlands — 1.17% (1.46%)		
6,391	GrandVision	111,901	0.03
113,603	Koninklijke Philips	3,020,864	0.67
62,493	Mylan	1,420,629	0.31
26,534	Qiagen	731,533	0.16
		5,284,927	1.17
	Spain — 0.29% (0.34%)		
31,625	Grifols	473,976	0.10
40,066	Grifols 'A'	848,590	0.19
		1,322,566	0.29
	Sweden — 0.17% (0.08%)		
43,282	Elekta	406,041	0.09
19,395	Swedish Orphan Biovitrum	364,410	0.08
		770,451	0.17
	Switzerland — 8.67% (8.81%)		
9,185	Lonza Group	1,946,436	0.43
268,197	Novartis	17,774,824	3.92
3,329	Roche	654,921	0.14
85,462	Roche (Part Certified)	16,946,292	3.74
6,488	Sonova	853,092	0.19
1,213	Straumann	616,945	0.14
5,370	Vifor Pharma	474,159	0.11
		39,266,669	8.67
	NORTH AMERICA — 60.62% (59.55%)		
	United States — 60.45% (59.38%)		
209,624	Abbott Laboratories	11,292,367	2.49

Portfolio Statement continued

Holding/ Nominal Value	Investment	Market Value £	% of Net Assets
	United States — (cont.)		
185,508	AbbVie	13,031,577	2.88
5,147	Abiomed	1,249,594	0.28
26,511	Alexion Pharmaceuticals	2,201,332	0.49
9,561	Align Technology	1,393,935	0.31
10,959	Alnylam Pharmaceuticals	696,611	0.15
79,444	Amgen	12,148,174	2.68
31,645	Anthem	6,194,287	1.37
62,433	Baxter International	3,241,591	0.72
32,797	Becton Dickinson & Company	5,608,007	1.24
24,473	Biogen	6,129,261	1.35
21,389	BioMarin Pharmaceutical	1,500,192	0.33
170,588	Boston Scientific	4,597,426	1.02
200,441	Bristol-Myers Squibb	7,409,682	1.64
37,740	Cardinal Health	1,326,319	0.29
86,908	Celgene	5,865,049	1.29
25,203	Centene	2,253,064	0.50
45,494	Cigna	6,717,832	1.48
5,834	Cooper Companies	1,125,575	0.25
15,497	DaVita	654,733	0.14
26,244	Dentsply Sirona	809,151	0.18
26,199	Edwards Lifesciences	3,051,459	0.67
116,844	Eli Lilly	10,365,916	2.29
158,642	Gilead Sciences	8,416,877	1.86
34,521	HCA Healthcare	3,365,656	0.74
18,573	Henry Schein	1,078,277	0.24
32,817	Hologic	1,035,691	0.23
17,092	Humana	3,688,844	0.81
10,355	IDEXX Laboratories	1,507,670	0.33
18,182	Illumina	4,335,707	0.96
21,259	Incyte	1,233,551	0.27
13,937	Intuitive Surgical	5,220,131	1.15
20,223	IQVIA	1,847,748	0.41
329,810	Johnson & Johnson	32,771,947	7.24
12,306	Laboratory Corporation of America	1,239,652	0.27
325,169	Merck & Company	19,295,378	4.26
711,011	Pfizer	23,913,648	5.28
16,420	Quest Diagnostics	1,057,104	0.23
9,934	Regeneron Pharmaceuticals	3,091,830	0.68
17,008	ResMed	1,462,962	0.32
42,192	Stryker	5,194,842	1.15
5,520	Teleflex	1,082,834	0.24
49,171	Thermo Fisher Scientific	8,630,224	1.91
117,229	UnitedHealth Group	21,954,177	4.85
10,172	Universal Health Services	941,581	0.21
11,683	Varian Medical Systems	1,092,967	0.24
31,637	Vertex Pharmaceuticals	4,313,168	0.95
6,011	WellCare Health Plans	1,089,261	0.24
25,188	Zimmer Biomet	2,051,465	0.45

Portfolio Statement continued

Holding/ Nominal Value	Investment	Market Value £	% of Net Assets
United States — (cont.)			
60,122	Zoetis	4,014,563	0.89
		273,790,889	60.45
Canada — 0.17% (0.17%)			
41,914	Bausch Health	747,972	0.17
SOUTH AMERICA — 0.16% (0.06%)			
Brazil — 0.16% (0.06%)			
25,401	Fleury	113,547	0.02
11,000	Hapvida Participacoes Investimento	71,493	0.02
54,700	Hypera	357,942	0.08
15,400	Notre Dame Intermedica Participacoes	94,693	0.02
31,400	Odontoprev	94,150	0.02
		731,825	0.16
AFRICA — 0.18% (0.27%)			
South Africa — 0.18% (0.27%)			
45,152	Aspen Pharmacare	341,418	0.07
164,803	Life Healthcare Group	234,353	0.05
172,659	Netcare	253,806	0.06
		829,577	0.18
ASIA — 7.03% (6.65%)			
Japan — 6.02% (5.64%)			
21,500	Alfresa	440,473	0.10
12,400	Asahi Intecc	398,169	0.09
246,300	Astellas Pharmaceutical	2,583,482	0.57
26,108	Chugai Pharmaceutical	1,222,146	0.27
81,200	Daiichi Sankyo	2,063,604	0.46
33,600	Eisai	2,074,324	0.46
8,900	Hisamitsu Pharmaceutical	387,044	0.09
47,500	Hoya	2,165,197	0.48
4,100	Kaken Pharmaceutical	151,941	0.03
4,100	Kissei Pharmaceutical	84,560	0.02
7,600	Kobayashi Pharmaceutical	412,863	0.09
5,500	Kyorin	92,972	0.02
30,600	Kyowa Hakko Kirin	469,295	0.10
18,900	Medipal	327,405	0.07
6,100	Miraca	110,429	0.02
27,600	Mitsubishi Tanabe Pharmaceutical	317,215	0.07
1,500	Mochida Pharmaceutical	99,690	0.02
9,200	Nihon Kohden	231,282	0.05
6,200	Nippon Shinyaku	298,739	0.07
13,800	Nipro	133,884	0.03
33,900	Olympus	816,714	0.18
53,300	Ono Pharmaceutical	883,658	0.20
52,000	Otsuka	1,690,027	0.37
10,600	PeptiDream	337,308	0.07
12,000	Rohto Pharmaceutical	260,495	0.06
43,800	Santen Pharmaceutical	511,317	0.11

Portfolio Statement continued

Holding/ Nominal Value	Investment	Market Value £	% of Net Assets
	Japan — (cont.)		
4,800	Sawai Pharmaceutical	182,737	0.04
35,200	Shionogi	1,616,985	0.36
20,000	Sumitomo Dainippon Pharmaceutical	516,512	0.11
9,770	Suzuken	400,883	0.09
22,800	Sysmex	915,271	0.20
5,275	Taisho Pharmaceutical	416,883	0.09
5,700	Takara Bio	106,771	0.02
92,200	Takeda Pharmaceutical	2,656,198	0.59
39,300	Terumo	1,697,444	0.38
7,700	Tsumura	170,767	0.04
		27,244,684	6.02
	Malaysia — 0.12% (0.09%)		
175,200	Hartalega	191,457	0.04
335,200	IHH Healthcare	351,652	0.08
		543,109	0.12
	South Korea — 0.69% (0.75%)		
9,851	Celltrion	1,488,570	0.33
6,409	Celltrion Healthcare	335,349	0.07
883	Hanmi Pharmaceutical	280,236	0.06
1,655	Hanmi Science	90,216	0.02
1,578	Samsung Biologics	428,319	0.10
6,427	SillaJen	321,472	0.07
1,072	Yuhan	170,993	0.04
		3,115,155	0.69
	Taiwan — 0.01% (0.01%)		
15,500	OBI Pharma	64,184	0.01
	Thailand — 0.19% (0.16%)		
1,107,000	Bangkok Dusit Medical Services	676,611	0.15
38,200	Bumrungrad Hospital	177,447	0.04
		854,058	0.19
	MIDDLE EAST — 0.34% (0.37%)		
	Israel — 0.34% (0.37%)		
110,371	Teva Pharmaceutical Industries	1,519,246	0.34
	PACIFIC BASIN — 1.97% (1.83%)		
	Australia — 1.81% (1.65%)		
17,291	Ansell	212,534	0.05
6,851	Cochlear	673,295	0.15
55,998	CSL	5,863,571	1.29
217,709	Healthscope	269,909	0.06
15,472	Ramsay Healthcare	497,083	0.11
55,651	Sonic Healthcare	670,055	0.15
		8,186,447	1.81
	New Zealand — 0.16% (0.18%)		
69,625	Fisher & Paykel Healthcare	483,617	0.10

Portfolio Statement continued

Holding/ Nominal Value	Investment	Market Value £	% of Net Assets
	New Zealand — (cont.)		
48,012	Ryman Healthcare	274,522	0.06
		758,139	0.16
	FORWARD CURRENCY CONTRACTS		
	— 0.00% (0.00%)		
USD(1,900,000)	Sold US Dollars		
GBP1,499,488	for Sterling (Expires 10/01/2019) ¹	12,755	—
USD(400,000)	Sold US Dollars		
GBP314,230	for Sterling (Expires 10/01/2019) ¹	1,234	—
		13,989	—
Portfolio of investments²		450,329,057	99.43
Net other assets		2,569,329	0.57
Total net assets		£452,898,386	100.00%

¹ Unlisted securities are valued at the Manager's best assessment of their fair and reasonable value.

² All investments are admitted to an official stock exchange unless otherwise stated.

Total purchases for the year: £60,872,879.

Total sales for the year: £65,820,259.

Independent Auditor's Report

Independent auditor's report to the Unitholders of Legal & General Global Health and Pharmaceuticals Index Trust ('the Trust')

Opinion

We have audited the financial statements of the Trust for the year ended 7 January 2019 which comprise the Statement of Total Return, the Statement of Changes in Net Assets Attributable to Unitholders, the Balance Sheet, the Related Notes and Distribution Tables for the Trust and the accounting policies set out on pages 20 to 21.

In our opinion, the financial statements:

- give a true and fair view, in accordance with UK accounting standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland, of the financial position of the Trust as at 7 January 2019 and of the net revenue and the net capital gains on the property of the Trust for the year then ended; and
- have been properly prepared in accordance with the Trust Deed, the Statement of Recommended Practice relating to UK Authorised Funds, and the COLL Rules.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) ("ISAs (UK)") and applicable law. Our responsibilities are described below. We have fulfilled our ethical responsibilities under, and are independent of the Trust in accordance with, UK ethical requirements including the FRC Ethical Standard.

We have received all the information and explanations which we consider necessary for the purposes of our audit and we believe that the audit evidence we have obtained is a sufficient and appropriate basis for our opinion.

The impact of uncertainties due to Britain exiting the European Union on our audit

Uncertainties related to the effects of Brexit are relevant to understanding our audit of the financial statements. All audits assess and challenge the reasonableness of estimates made by the directors, and related disclosures and the appropriateness of the going concern basis of preparation of the financial statements. All of these depend on assessments of the future economic environment and the Trust's future prospects and performance.

Brexit is one of the most significant economic events for the UK, and at the date of this report its effects are subject to unprecedented levels of uncertainty of outcomes, with the full range of possible effects unknown. We applied a standardised firm-wide approach in response to that uncertainty when assessing the Trust's future prospects and performance. However, no audit should be expected to predict the unknowable factors or all possible future implications for a trust and this is particularly the case in relation to Brexit.

Going concern

The Manager has prepared the financial statements on the going concern basis as they do not intend to liquidate the Trust to cease their operations, and as they have concluded that the Trust's financial position means that this is realistic. They have also concluded that there are no material uncertainties that could have cast significant doubt over their ability to continue as a going concern for at least a year from the date of approval of the financial statements ("the going concern period").

Independent Auditor's Report continued

We are required to report to you if we have concluded that the use of the going concern basis of accounting is inappropriate or there is an undisclosed material uncertainty that may cast significant doubt over the use of that basis for a period of at least a year from the date of approval of the financial statements. In our evaluation of the Manager's conclusions, we considered the inherent risks to the Trust's business model, including the impact of Brexit, and analysed how those risks might affect the Trust's financial resources or ability to continue operations over the going concern period. We have nothing to report in these respects.

However, as we cannot predict all future events or conditions and as subsequent events may result in outcomes that are inconsistent with judgements that were reasonable at the time they were made, the absence of reference to a material uncertainty in this auditor's report is not a guarantee that the Trust will continue in operation.

Other information

The Manager (Legal & General (Unit Trust Managers) Limited) is responsible for the other information presented in the Annual Manager's Report together with the financial statements. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except as explicitly stated below, any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether, based on our financial statements audit work, the information therein is materially misstated or inconsistent with the financial statements or our audit knowledge. Based solely on that work:

- we have not identified material misstatements in the other information; and
- in our opinion the information given in Manager's Report for the financial year is consistent with the financial statements.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where under the COLL Rules we are required to report to you if, in our opinion:

- proper accounting records for the Trust have not been kept; or
- the financial statements are not in agreement with the accounting records.

Manager's responsibilities

As explained more fully in their statement set out on page 6, the Manager is responsible for: the preparation of financial statements that give a true and fair view; such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error; assessing the Trust's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and using the going concern basis of accounting unless they either intend to liquidate the Trust or to cease operations, or have no realistic alternative but to do so.

Independent Auditor's Report continued

Auditor's responsibilities

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue our opinion in an auditor's report. Reasonable assurance is a high level of assurance, but does not guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

A fuller description of our responsibilities is provided on the FRC's website at www.frc.org.uk/auditorsresponsibilities.

The purpose of our audit work and to whom we owe our responsibilities

This report is made solely to the Trust's unitholders, as a body, in accordance with Rule 4.5.12 of the Collective Investment Schemes sourcebook ('the COLL Rules') issued by the Financial Conduct Authority under section 247 of the Financial Services and Markets Act 2000. Our audit work has been undertaken so that we might state to the Trust's unitholders those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Trust and the Trust's unitholders as a body, for our audit work, for this report, or for the opinions we have formed.

Grant Archer
for and on behalf of KPMG LLP, Statutory Auditor
Chartered Accountants
15 Canada Square,
London E14 5GL
26 February 2019

Financial Statements

Statement of Total Return for the year ended 7 January 2019

Notes	07/01/19		07/01/18	
	£	£	£	£
Income				
Net capital gains	3	23,203,704		24,434,344
Revenue	4	9,013,722	6,777,118	
Expenses	5	(1,955,568)	(1,925,443)	
Interest payable and similar charges	7	(137)	(1,869)	
Net revenue before taxation		<u>7,058,017</u>	<u>4,849,806</u>	
Taxation	6	(966,734)	(796,186)	
Net revenue after taxation for the year		<u>6,091,283</u>	<u>4,053,620</u>	
Total return before distributions		29,294,987	28,487,964	
Distributions	7	(6,092,947)	(4,055,261)	
Change in net assets attributable to Unitholders from investment activities		<u>£23,202,040</u>	<u>£24,432,703</u>	

Statement of Change in Net Assets attributable to Unitholders for the year ended 7 January 2019

	07/01/19		07/01/18	
	£	£	£	£
Opening net assets attributable to Unitholders		435,267,034		267,859,162
Amounts received on issue of units		47,992,249	167,935,941	
Amounts paid on cancellation of units		(56,849,026)	(27,803,705)	
		(8,856,777)		140,132,236
Change in net assets attributable to Unitholders from investment activities		23,202,040		24,432,703
Retained distributions on accumulation units		<u>3,286,089</u>		<u>2,842,933</u>
Closing net assets attributable to Unitholders		<u>£452,898,386</u>		<u>£435,267,034</u>

Financial Statements continued

Balance Sheet as at 7 January 2019

	Notes	07/01/19 £	07/01/18 £
ASSETS			
Fixed assets:			
Investments		450,329,057	432,049,467
Current assets:			
Debtors	8	2,825,200	1,938,096
Cash and bank balances	9	5,449,855	5,158,086
Total assets		<u>458,604,112</u>	<u>439,145,649</u>
LIABILITIES			
Creditors:			
Bank overdrafts	9	(2,628,720)	(124)
Distributions payable		(2,702,947)	(2,523,684)
Other creditors	10	(374,059)	(1,354,807)
Total liabilities		<u>(5,705,726)</u>	<u>(3,878,615)</u>
Net assets attributable to Unitholders		<u>£452,898,386</u>	<u>£435,267,034</u>

Notes to the Financial Statements

1. Statement of Compliance

The Financial Statements have been prepared in compliance with UK Financial Reporting Standard 102 (FRS 102) and in accordance with the Statement of Recommended Practice for UK Authorised Funds issued by the Investment Management Association in May 2014 (2014 SORP).

2. Summary of Significant Accounting Policies

(a) Basis of Preparation

The Financial Statements have been prepared on a going concern basis, under the historical cost convention as modified by the revaluation of certain financial assets and liabilities measured at fair value through profit or loss.

The principal accounting policies which have been applied consistently are set out below.

(b) Functional and Presentation Currency

The functional and presentation currency of the Trust is Sterling.

(c) Recognition of Revenue

Revenue from quoted equities and non-equity shares is recognised net of attributable tax credits when the security is quoted ex-dividend. Revenue from unquoted equity investments is recognised net of attributable tax credits when the dividend is declared.

Overseas revenue received after the deduction of withholding tax is shown gross of taxation, with the taxation consequences shown within the taxation charge.

Special dividends are treated as either revenue or capital depending on the facts of each particular case.

All other revenue is recognised on an accruals basis.

(d) Treatment of Expenses

All expenses (other than those relating to the purchase and sale of investments) are charged against revenue on an accruals basis.

(e) Distribution Policy

The policy is to distribute all available revenue, after deduction of those expenses which are chargeable in calculating the distribution, on an annual basis, in accordance with the COLL.

Fund management fees are deducted from revenue for the purpose of calculating the distribution.

The ordinary element of stock dividends is treated as revenue and forms part of the distribution. In the case of an enhanced stock dividend, the value of the enhancement is treated as capital and does not form part of the distribution.

Distributions which have remained unclaimed by Unitholders for over six years are credited to the capital property of the Trust.

Notes to the Financial Statements continued

2. Summary of Significant Accounting Policies continued

(f) Basis of Valuation of Investments

All investments are valued at their fair value as at 3pm on 7 January 2019, being the last working day of the accounting year. The fair value for non-derivative securities is bid market price.

Where values cannot be readily determined, the securities are valued at the Manager's best assessment of their fair and reasonable value.

(g) Taxation

Provision is made for taxation at current rates on the excess of investment revenue over expenses, with relief for overseas taxation taken where appropriate.

Deferred tax is provided for on all timing differences that have originated but not reversed by the balance sheet date, other than those differences that are regarded as permanent. Any liability to deferred tax is provided for at the average rate of tax expected to apply.

(h) Foreign Exchange

Transactions in foreign currencies are translated at the rate of exchange ruling on the date of the transaction. Where applicable, assets and liabilities denominated in foreign currencies are translated into Sterling at the rates of exchange ruling at 3pm on 7 January 2019, being the last working day of the accounting year.

3. Net capital gains

	07/01/19	07/01/18
	£	£
The net capital gains during the year comprise:		
Non-derivative securities	23,212,988	24,416,611
Forward currency contracts	23,151	110,180
Currency losses	(32,435)	(92,447)
Net capital gains	<u>23,203,704</u>	<u>24,434,344</u>

4. Revenue

	07/01/19	07/01/18
	£	£
UK Franked dividends	831,264	691,610
Taxable overseas dividends	—	58,264
Non-taxable overseas dividends	8,071,288	6,005,477
Franked stock dividends	104,786	21,046
Bank interest	<u>6,384</u>	<u>721</u>
	<u>9,013,722</u>	<u>6,777,118</u>

Notes to the Financial Statements continued

5. Expenses

Payable to the Manager,
associates of the Manager
and agents of either of them:

Fund management fees

Total expenses

	07/01/19	07/01/18
	£	£
Fund management fees	1,955,568	1,925,443
Total expenses	1,955,568	1,925,443

Audit fees of £8,900 plus VAT of £1,780 have been borne by the Manager out of its fund management fee. In the prior year, the total audit fee was £8,997 plus VAT of £1,799.

Notes to the Financial Statements continued

6. Taxation

(a) Analysis of taxation charge in year

	07/01/19	07/01/18
	£	£
Overseas tax	966,734	796,186
Current tax [note 6(b)]	966,734	796,186
Deferred tax [note 6(c)]	—	—
Total taxation	<u>966,734</u>	<u>796,186</u>

(b) Factors affecting taxation charge for the year

The current tax charge excludes capital gains and losses for the reason that Authorised Unit Trusts are not subject to Corporation Tax on these items. Current tax differs from taxation assessed on net revenue before taxation as follows:

Net revenue before taxation	<u>7,058,017</u>	<u>4,849,806</u>
Net revenue before taxation multiplied by the applicable rate of Corporation tax of 20% (2018: 20%)	1,411,603	969,961
Effects of:		
DTR expensed	—	(1,748)
Overseas tax	966,734	796,186
Revenue not subject to taxation	(1,801,467)	(1,343,626)
Excess management expenses not utilised	<u>389,864</u>	<u>375,413</u>
Current tax	<u>966,734</u>	<u>796,186</u>

(c) Provision for deferred tax

There is no deferred tax provision in the current or preceding year. At the year end there is a potential deferred tax asset of £2,001,675 (7 January 2018: £1,611,811) due to surplus management expenses.

It is unlikely the Trust will generate sufficient taxable profits in the future to utilise this amount and therefore no deferred tax asset has been recognised (7 January 2018: same).

Notes to the Financial Statements continued

7. Distributions

The distributions take account of revenue received on the creation of units and revenue deducted on the cancellation of units and comprise:

	07/01/19	07/01/18
	£	£
Final distribution	<u>5,989,036</u>	<u>5,366,617</u>
	5,989,036	5,366,617
Add: Revenue deducted on cancellation of units	538,421	192,062
Less: Revenue received on creation of units	<u>(434,510)</u>	<u>(1,503,418)</u>
Distributions for the year	6,092,947	4,055,261
Interest payable and similar charges		
Bank overdraft interest	<u>137</u>	<u>1,869</u>
	<u>6,093,084</u>	<u>4,057,130</u>

The differences between the net revenue after taxation and the distributions for the year are as follows:

	07/01/19	07/01/18
	£	£
Net revenue after taxation for the year	6,091,283	4,053,620
Equalisation effect of conversions	<u>1,664</u>	<u>1,641</u>
Distributions for the year	6,092,947	4,055,261

8. Debtors

	07/01/19	07/01/18
	£	£
Accrued revenue	428,038	382,657
Amounts receivable for creation of units	1,364,997	211,999
Overseas tax recoverable	1,032,165	593,627
Receivable for foreign exchange contracts	—	734
Sales awaiting settlement	<u>—</u>	<u>749,079</u>
	<u>2,825,200</u>	<u>1,938,096</u>

Notes to the Financial Statements continued

9. Net uninvested cash

	07/01/19	07/01/18
	£	£
Cash and bank balances	5,449,855	5,158,086
Bank overdrafts	<u>(2,628,720)</u>	<u>(124)</u>
Net uninvested cash	<u>2,821,135</u>	<u>5,157,962</u>

10. Other creditors

	07/01/19	07/01/18
	£	£
Accrued expenses	198,823	214,806
Amounts payable for cancellation of units	5,001	1,140,001
Payable for foreign exchange contracts	2,553	—
Purchases awaiting settlement	<u>167,682</u>	<u>—</u>
	<u>374,059</u>	<u>1,354,807</u>

11. Contingent liabilities and outstanding commitments

Contingent liabilities and outstanding commitments at the balance sheet date were:

	07/01/19	07/01/18
	£	£
Commitments on warrants	<u>—</u>	<u>21,503</u>
Total	<u>—</u>	<u>21,503</u>

Notes to the Financial Statements continued

12. Financial Instruments and Associated Risks

The investments of a Trust in financial securities and derivatives are subject to normal market fluctuations and other risks inherent in investing in such instruments. Legal & General (Unit Trust Managers) Limited (UTM) is the Authorised Fund Manager and has responsibility for ensuring appropriate risk management processes are implemented for each Unit Trust.

The UTM Board has delegated the risk oversight function to the Fund Manager Oversight Committee (FMOC), a committee of the Legal & General Investment Management (Holdings) Limited (LGIMH) Board that meets monthly. The primary objective of the FMOC is to ensure proper oversight of the investment management activities and associated services performed by LGIM, its delegates and other Fund Managers, under the Investment Management Agreement (IMA), on behalf of UTM in its capacity as Authorised Fund Manager. The committee consists of senior members of LGIMH and members of the UTM Board. Other senior staff members are also in attendance, as required by the agenda.

Each Trust has Investment Guidelines, an Investment Objective and Investment Restrictions, against which the fund manager will operate. These are set out in Schedule 1 of the IMA between LGIM and UTM. The Schedule is maintained by each fund manager, reviewed by the LGIM Operational Risk and Compliance Teams and approved senior members of LGIMH on behalf of the UTM board. The Schedule provides the detail needed to determine the risk profile for each fund. Fund managers are not permitted to invest into any new instruments without first gaining approval from UTM.

The Investment Objective and Policy of this Trust is detailed on page 2.

(a) Market Risk arising from other price risk

Market Risk arises mainly from uncertainty about future prices. It represents the potential loss the Trust may suffer through holding market positions in the face of market movements.

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting similar instruments traded in the market.

The assets held by the Trust can be seen in the Portfolio Statement starting on page 9. Movements in the prices of these investments result in movements in the performance of the Trust. The Manager adheres to the investment guidelines established in the Trust Deed, the Prospectus, the COLL and the Trust's IOG, and in this way, monitors and controls the exposure to risk from any type of security, sector or issuer.

At 7 January 2019, if the price of the investments held by the Trust increased or decreased by 5%, with all other variables remaining constant, then the net assets attributable to unitholders would increase or decrease by approximately £22,516,453 (7 January 2018: £21,602,473).

Notes to the Financial Statements continued

12. Financial Instruments and Associated Risks continued

(b) Interest Rate Risk

Interest Rate Risk is the risk of movements in the value of financial instruments as a result of fluctuations in interest rates.

The Trust's only interest bearing financial instruments were its bank balances and overdraft facilities as disclosed in note 9. Cash is deposited and overdraft facilities utilised on normal commercial terms and earn or bear interest based on LIBOR or its overseas equivalent.

In the event of a change in interest rates, there would be no material impact upon the assets of the Trust.

(c) Foreign Currency Risk

Foreign Currency Risk is the risk of movements in the value of financial instruments as a result of fluctuations in exchange rates. This risk may be managed by the use of forward currency contracts or currency futures as necessary.

Forward currency contracts were utilised during the current and preceding year.

At 7 January 2019, if the value of Sterling increased or decreased by 1% against all currencies, with all other variables remaining constant, then the net assets attributable to unitholders would increase or decrease by approximately £4,269,195 (7 January 2018: £4,110,977).

The direct foreign currency profile of the Trust's net assets at the balance sheet date was:

07/01/19 Currency	Net foreign currency assets		
	Monetary exposures £'000	Non-monetary exposures £'000	Total £'000
Australian Dollar	229	8,186	8,415
Brazilian Real	—	732	732
Canadian Dollar	2	748	750
Danish Krone	107	13,225	13,332
Euro	144	33,135	33,279
Hungarian Forint	—	265	265
Israeli Shekel	250	1,519	1,769
Japanese Yen	139	27,245	27,384
Malaysian Ringgit	—	543	543
Mexican Peso	2	—	2
New Zealand Dollar	7	758	765
Singapore Dollar	6	—	6
South African Rand	9	830	839
South Korean Won	—	3,115	3,115
Swedish Krona	1	770	771
Swiss Franc	935	39,267	40,202
Taiwan Dollar	7	64	71
Thai Baht	—	854	854
US Dollar	94	293,730	293,824

Notes to the Financial Statements continued

12. Financial Instruments and Associated Risks continued

(c) Foreign Currency Risk continued

07/01/18 Currency	Net foreign currency assets		Total £'000
	Monetary exposures £'000	Non-monetary exposures £'000	
Australian Dollar	16	7,180	7,196
Brazilian Real	1	275	276
Canadian Dollar	32	742	774
Danish Krone	56	13,122	13,178
Euro	59	37,054	37,113
Hungarian Forint	3	345	348
Israeli Shekel	—	1,593	1,593
Japanese Yen	26	24,555	24,581
Malaysian Ringgit	—	382	382
Mexican Peso	2	—	2
New Zealand Dollar	37	800	837
South African Rand	36	1,194	1,230
South Korean Won	2	3,254	3,256
Swedish Krona	7	362	369
Swiss Franc	570	38,326	38,896
Taiwan Dollar	7	57	64
Thai Baht	—	690	690
US Dollar	535	279,778	280,313

(d) Credit Risk

Credit Risk is the risk of suffering financial loss as a result of a counterparty to a financial transaction being unable to fulfil their financial obligations as they fall due.

This risk is managed by appraising the credit profile of financial instruments and issuers in line with the Trust's investment objective and policy.

(e) Liquidity Risk

Liquidity Risk relates to the capacity to meet liabilities as they fall due. The primary source of this risk to the Trust is the liability to Unitholders for any cancellation of units.

This risk is minimised by holding a large proportion of readily realisable assets, cash balances and via access to overdraft facilities.

(f) Derivative Risk - Sensitivity Analysis

Derivative Risk arises from uncertainty about future market movements. This risk is managed by the policies shown within Market risk.

At the balance sheet date, no derivatives were held that could impact the Trust in a significant way (7 January 2018: same).

Notes to the Financial Statements continued

12. Financial Instruments and Associated Risks continued

(g) Fair Value

The fair value of a financial instrument is the amount for which it could be exchanged between knowledgeable, willing parties in an arm's length transaction. There is no material difference between the value of the financial assets and liabilities, as shown in the financial statements, and their fair value.

The Statement of Recommended Practice for Financial Statements of UK Authorised Funds issued by the Investment Management Association in May 2014 requires the classification of the Trust's financial instruments held at the year end into a 3 tiered fair value hierarchy. The 3 tiers of the hierarchy and the classification of the Trust's financial instruments as at the balance sheet date were:

07/01/19	Assets	Liabilities
Basis of Valuation	£	£
Level 1 - Quoted Prices	450,315,068	—
Level 2 - Observable Market Data	13,989	—
Level 3 - Unobservable Data	—	—
Total	450,329,057	—

07/01/18	Assets	Liabilities
Basis of Valuation	£	£
Level 1 - Quoted Prices	432,049,467	—
Level 2 - Observable Market Data	—	—
Level 3 - Unobservable Data	—	—
Total	432,049,467	—

Level 1

The unadjusted quoted price in an active market for assets or liabilities that the entity can access at the measurement date.

Level 2

Valuation techniques using observable inputs other than quoted prices within Level 1.

Level 3

Valuation techniques using unobservable inputs.

Notes to the Financial Statements continued

13. Portfolio transaction costs

07/01/19	Value	Commissions		Taxes		Total
Purchases	£'000	£'000	%	£'000	%	£'000
Equities	60,841	15	0.02	17	0.03	60,873
Total	60,841	15	0.02	17	0.03	60,873

07/01/19	Value	Commissions		Taxes		Total
Sales	£'000	£'000	%	£'000	%	£'000
Equities	65,836	(15)	0.02	(1)	—	65,820
Total	65,836	(15)	0.02	(1)	—	65,820

Commissions and taxes as % of average net assets

Commissions 0.01%

Taxes 0.00%

07/01/18	Value	Commissions		Taxes		Total
Purchases	£'000	£'000	%	£'000	%	£'000
Equities	173,213	52	0.03	59	0.03	173,324
Total	173,213	52	0.03	59	0.03	173,324

07/01/18	Value	Commissions		Taxes		Total
Sales	£'000	£'000	%	£'000	%	£'000
Equities	30,862	(6)	0.02	(1)	—	30,855
Total	30,862	(6)	0.02	(1)	—	30,855

Commissions and taxes as % of average net assets

Commissions 0.02%

Taxes 0.02%

Transaction costs consist of expenses incurred in the process of the purchase and sales of securities above the cost of the securities.

The average portfolio dealing spread, including the effect of foreign exchange, as at the balance sheet date was 0.14% (7 January 2018: 0.09%).

Notes to the Financial Statements continued

14. Unit classes

A list of unit classes in issue and the fund management fee on each unit class can be found on page 42. The net asset value per unit of each unit class and the number of units in each class are given in the comparative tables on pages 35 to 40. The distributions per unit class are given in the distribution table on page 33. All classes have the same rights on winding up.

R-Class	Distribution	Accumulation
Opening Units	11,699,403	160,986,359
Units issued	733,740	5,342,028
Units cancelled	(1,025,509)	(6,388,170)
Units converted	(135,864)	(860,440)
Closing Units	11,271,770	159,079,777

F-Class	Distribution	Accumulation
Opening Units	1,216	291,464
Units issued	303,399	102,372
Units cancelled	(15,722)	(12,934)
Units converted	—	—
Closing Units	288,893	380,902

I-Class	Distribution	Accumulation
Opening Units	290,378,958	201,188,412
Units issued	21,776,274	38,375,137
Units cancelled	(24,680,742)	(46,516,081)
Units converted	51,624	849,172
Closing Units	287,526,114	193,896,640

15. Ultimate controlling party and related party transactions

The Manager is regarded as a related party to the Trust because it provides key management personnel services to the Trust. The ultimate controlling party of the Manager is Legal & General Group Plc. Subsidiaries of Legal & General Group Plc are also considered related parties to the Trust.

Legal & General (Unit Trust Managers) Limited acts as the principal on all the transactions of the units in the Trust. The aggregated monies received through creations or paid on cancellations are disclosed in the statement of change in net assets attributable to unitholders.

Equalisation amounts relating to creations and cancellations of units are shown within note 7. Fees received by the Authorised Fund Manager from the Trust plus any rebates paid by the Authorised Fund Manager to the Trust are shown within notes 3, 4 and 5 as applicable. Any outstanding fees, amounts outstanding on creations or cancellations of units in the Trust, or rebates receivable by the Trust from the Manager are shown within notes 8 and 10 as applicable.

At the year end, the Manager and its associates held nil% (nil% as at 7 January 2018) of the Trust's units in issue.

Notes to the Financial Statements continued

16. Post balance sheet market movements

As at the close of business on the balance sheet date the Net Asset Value per R-Class distribution unit was 62.53p. The Net Asset Value per R-Class distribution unit for the Trust as at 3pm on 21 February 2019 was 64.89p. This represents an increase of 3.77% from the year end value.

Distribution Tables

Distribution Table for the year ended 7 January 2019

Group 1: units purchased prior to a distribution period.

Group 2: units purchased during a distribution period.

Equalisation is the average amount of revenue included in the purchase price of all Group 2 units and is refunded to the holders of these units as a return of capital. As capital it is not liable to Income Tax but must be deducted from the cost of units for Capital Gains Tax purposes.

Final dividend distribution in pence per unit			Period	
			08/01/18	to 07/01/19
R-Class			Distribution	Distribution
Distribution Units			07/03/19	07/03/18
Group 1	Revenue	Equalisation	0.6077	0.4170
Group 2	0.2496	0.3581	0.6077	0.4170
R-Class			Distribution	Distribution
Accumulation Units			07/03/19	07/03/18
Group 1	Revenue	Equalisation	0.6847	0.4666
Group 2	0.2990	0.3857	0.6847	0.4666
F-Class			Distribution	Distribution
Distribution Units			07/03/19	07/03/18
Group 1	Revenue	Equalisation	0.8274	0.7713
Group 2	0.2011	0.6263	0.8274	0.7713
F-Class			Distribution	Distribution
Accumulation Units			07/03/19	07/03/18
Group 1	Revenue	Equalisation	0.9634	0.8872
Group 2	0.1557	0.8077	0.9634	0.8872
I-Class			Distribution	Distribution
Distribution Units			07/03/19	07/03/18
Group 1	Revenue	Equalisation	0.9154	0.8522
Group 2	0.3967	0.5187	0.9154	0.8522
I-Class			Distribution	Distribution
Accumulation Units			07/03/19	07/03/18
Group 1	Revenue	Equalisation	1.1310	1.0383
Group 2	0.3897	0.7413	1.1310	1.0383

Trust Information

The Comparative Tables on pages 35 to 40 give the performance of each active share class in the Trust.

The 'Return after charges' disclosed in the Comparative Tables is calculated as the return after operating charges per unit divided by the opening net asset value per unit. It differs from the Trust's performance disclosed in the Manager's report, which is calculated based on the latest published price.

Portfolio transaction costs are incurred when investments are bought or sold by a fund in order to achieve the investment objective. These transaction costs affect an investor in different ways depending on whether they are joining, leaving or continuing with their investment in the Trust.

Direct transaction costs include broker commission and taxes. Broker commission includes the fee paid to a broker to execute the trades and research costs.

In addition, there are indirect portfolio transaction costs arising from the 'dealing spread' – the difference between the buying and selling prices of underlying investments in the portfolio. Unlike shares whereby broker commissions and stamp duty are paid by a fund on each transaction, other types of investments (such as bonds, money instruments, derivatives, collective investment schemes) do not have separately identifiable transaction costs; these costs form part of the dealing spread. Dealing spreads vary considerably depending on the transaction value and money market sentiment.

Trust Information continued

Comparative Tables

R-Class Distribution Units

Change in Net Asset Value per Unit

Accounting Year ending	07/01/19 (pence per unit)	07/01/18 (pence per unit)	07/01/17 (pence per unit)
Opening net asset value per unit	59.37	54.86	47.30
Return before operating charges*	4.26	5.53	8.48
Operating charges (calculated on average price)	(0.49)	(0.60)	(0.59)
Return after operating charges*	3.77	4.93	7.89
Distributions on income units	(0.61)	(0.42)	(0.33)
Closing net asset value per unit	62.53	59.37	54.86
* after direct transaction costs of:	0.01	0.02	0.01

Performance

Return after charges	6.35%	8.99%	16.68%
----------------------	-------	-------	--------

Other Information

Closing net asset value (£)	7,047,948	6,945,908	6,607,055
Closing number of units	11,271,770	11,699,403	12,043,433
Operating charges [†]	0.79%	1.03%	1.15%
Direct transaction costs	0.01%	0.03%	0.02%

Prices

Highest unit price	68.68p	61.17p	56.97p
Lowest unit price	54.13p	52.68p	43.31p

[†] Operating charges, otherwise known as the OCF is the ratio of the Trust's total disclosable costs (excluding overdraft interest) to the average net assets of the Trust. The OCF is intended to provide a reliable figure which gives the most accurate measure of what it costs to invest in a Trust and is calculated based on the last period's figures.

Past performance is not a guide to future performance.

The price of units and any income from them may go down as well as up.

Exchange rate changes may cause the value of any overseas investments to rise or fall.

Trust Information continued

Comparative Tables continued

R-Class Accumulation Units

Change in Net Asset Value per Unit

Accounting Year ending	07/01/19 (pence per unit)	07/01/18 (pence per unit)	07/01/17 (pence per unit)
Opening net asset value per unit	66.89	61.37	52.60
Return before operating charges*	4.79	6.19	9.42
Operating charges (calculated on average price)	(0.55)	(0.67)	(0.65)
Return after operating charges*	4.24	5.52	8.77
Distributions	(0.68)	(0.47)	(0.37)
Retained distributions on accumulation units	0.68	0.47	0.37
Closing net asset value per unit	71.13	66.89	61.37
* after direct transaction costs of:	0.01	0.02	0.01

Performance

Return after charges	6.34%	8.99%	16.67%
----------------------	-------	-------	--------

Other Information

Closing net asset value (£)	113,151,571	107,678,286	100,139,971
Closing number of units	159,079,777	160,986,359	163,161,625
Operating charges†	0.79%	1.03%	1.15%
Direct transaction costs	0.01%	0.03%	0.02%

Prices

Highest unit price	77.38p	68.43p	63.36p
Lowest unit price	60.98p	58.94p	48.16p

† Operating charges, otherwise known as the OCF is the ratio of the Trust's total disclosable costs (excluding overdraft interest) to the average net assets of the Trust. The OCF is intended to provide a reliable figure which gives the most accurate measure of what it costs to invest in a Trust and is calculated based on the last period's figures.

Past performance is not a guide to future performance.

The price of units and any income from them may go down as well as up.

Exchange rate changes may cause the value of any overseas investments to rise or fall.

Trust Information continued

Comparative Tables continued

F-Class Distribution Units

Change in Net Asset Value per Unit

Accounting Year ending	07/01/19 (pence per unit)	07/01/18 (pence per unit)	07/01/17 (pence per unit)
Opening net asset value per unit	59.54	55.02	47.45
Return before operating charges*	4.27	5.55	8.52
Operating charges (calculated on average price)	(0.29)	(0.26)	(0.23)
Return after operating charges*	3.98	5.29	8.29
Distributions on income units	(0.83)	(0.77)	(0.72)
Closing net asset value per unit	62.69	59.54	55.02
* after direct transaction costs of:	0.01	0.02	0.01

Performance

Return after charges	6.68%	9.61%	17.47%
----------------------	-------	-------	--------

Other Information

Closing net asset value (£)	181,105	724	669
Closing number of units	288,893	1,216	1,216
Operating charges [†]	0.45%	0.45%	0.45%
Direct transaction costs	0.01%	0.03%	0.02%

Prices

Highest unit price	69.09p	61.49p	57.40p
Lowest unit price	54.32p	52.83p	43.45p

[†] Operating charges, otherwise known as the OCF is the ratio of the Trust's total disclosable costs (excluding overdraft interest) to the average net assets of the Trust. The OCF is intended to provide a reliable figure which gives the most accurate measure of what it costs to invest in a Trust and is calculated based on the last period's figures.

Past performance is not a guide to future performance.

The price of units and any income from them may go down as well as up.

Exchange rate changes may cause the value of any overseas investments to rise or fall.

Trust Information continued

Comparative Tables continued

F-Class Accumulation Units

Change in Net Asset Value per Unit

Accounting Year ending	07/01/19 (pence per unit)	07/01/18 (pence per unit)	07/01/17 (pence per unit)
Opening net asset value per unit	69.35	63.25	53.83
Return before operating charges*	4.98	6.40	9.68
Operating charges (calculated on average price)	(0.33)	(0.30)	(0.26)
Return after operating charges*	4.65	6.10	9.42
Distributions	(0.96)	(0.89)	(0.82)
Retained distributions on accumulation units	0.96	0.89	0.82
Closing net asset value per unit	74.00	69.35	63.25
* after direct transaction costs of:	0.01	0.02	0.01

Performance

Return after charges	6.71%	9.64%	17.50%
----------------------	-------	-------	--------

Other Information

Closing net asset value (£)	281,854	202,122	147,862
Closing number of units	380,902	291,464	233,776
Operating charges†	0.45%	0.45%	0.45%
Direct transaction costs	0.01%	0.03%	0.02%

Prices

Highest unit price	80.48p	70.75p	65.18p
Lowest unit price	63.29p	60.76p	49.32p

† Operating charges, otherwise known as the OCF is the ratio of the Trust's total disclosable costs (excluding overdraft interest) to the average net assets of the Trust. The OCF is intended to provide a reliable figure which gives the most accurate measure of what it costs to invest in a Trust and is calculated based on the last period's figures.

Past performance is not a guide to future performance.

The price of units and any income from them may go down as well as up.

Exchange rate changes may cause the value of any overseas investments to rise or fall.

Trust Information continued

Comparative Tables continued

I-Class Distribution Units

Change in Net Asset Value per Unit

Accounting Year ending	07/01/19 (pence per unit)	07/01/18 (pence per unit)	07/01/17 (pence per unit)
Opening net asset value per unit	59.45	54.92	47.35
Return before operating charges*	4.27	5.56	8.53
Operating charges (calculated on average price)	(0.19)	(0.18)	(0.16)
Return after operating charges*	4.08	5.38	8.37
Distributions on income units	(0.92)	(0.85)	(0.80)
Closing net asset value per unit	62.61	59.45	54.92
* after direct transaction costs of:	0.01	0.02	0.01

Performance

Return after charges	6.86%	9.80%	17.68%
----------------------	-------	-------	--------

Other Information

Closing net asset value (£)	180,029,808	172,640,075	34,249,394
Closing number of units	287,526,114	290,378,958	62,357,826
Operating charges [†]	0.31%	0.31%	0.31%
Direct transaction costs	0.01%	0.03%	0.02%

Prices

Highest unit price	69.09p	61.48p	57.40p
Lowest unit price	54.28p	52.77p	43.39p

[†] Operating charges, otherwise known as the OCF is the ratio of the Trust's total disclosable costs (excluding overdraft interest) to the average net assets of the Trust. The OCF is intended to provide a reliable figure which gives the most accurate measure of what it costs to invest in a Trust and is calculated based on the last period's figures.

Past performance is not a guide to future performance.

The price of units and any income from them may go down as well as up.

Exchange rate changes may cause the value of any overseas investments to rise or fall.

Trust Information continued

Comparative Tables continued

I-Class Accumulation Units

Change in Net Asset Value per Unit

Accounting Year ending	07/01/19 (pence per unit)	07/01/18 (pence per unit)	07/01/17 (pence per unit)
Opening net asset value per unit	73.46	66.91	56.86
Return before operating charges*	5.28	6.77	10.24
Operating charges (calculated on average price)	(0.24)	(0.22)	(0.19)
Return after operating charges*	5.04	6.55	10.05
Distributions	(1.13)	(1.04)	(0.96)
Retained distributions on accumulation units	1.13	1.04	0.96
Closing net asset value per unit	78.50	73.46	66.91
* after direct transaction costs of:	0.01	0.02	0.01

Performance

Return after charges	6.86%	9.79%	17.68%
----------------------	-------	-------	--------

Other Information

Closing net asset value (£)	152,206,100	147,799,919	126,714,211
Closing number of units	193,896,640	201,188,412	189,384,223
Operating charges†	0.31%	0.31%	0.31%
Direct transaction costs	0.01%	0.03%	0.02%

Prices

Highest unit price	85.37p	74.89p	68.93p
Lowest unit price	67.07p	64.28p	52.10p

† Operating charges, otherwise known as the OCF is the ratio of the Trust's total disclosable costs (excluding overdraft interest) to the average net assets of the Trust. The OCF is intended to provide a reliable figure which gives the most accurate measure of what it costs to invest in a Trust and is calculated based on the last period's figures.

Past performance is not a guide to future performance.

The price of units and any income from them may go down as well as up.

Exchange rate changes may cause the value of any overseas investments to rise or fall.

Risk and Reward Profile (unaudited)



- This risk and reward indicator is based on historical data which may not be a reliable indication of the Trust's risk and reward category in the future.
- The category number highlighted above reflects the rate at which the Trust's unit price has moved up and down in the past. If the Trust has less than five years' track record, the number also reflects the rate at which the Index the Trust tracks has moved up and down in the past. Higher numbers mean the potential reward could be greater, but this comes with increased risk of losing money.
- The Trust is in category five because it invests in company shares which are sensitive to variations in the stock market. The value of company shares can change substantially over short periods of time. Company shares are generally considered to be higher risk investments than bonds or cash.
- The Trust's category is not guaranteed to remain the same and may change over time.
- Even a trust in the lowest category is not a risk free investment.

General Information (unaudited)

Constitution

Launch date:	1 November 2000
Period end date for distribution:	7 January
Distribution date:	7 March
Minimum initial lump sum investment:	R-Class £100 F-Class* £500 I-Class £1,000,000
Valuation point:	3pm
Fund management fees:	R-Class Annual 0.69%† (0.95% Prior to 1 June 2018) F-Class* Annual 0.45% I-Class Annual 0.31%
Initial charge:	Nil for all existing unit classes

* F-Class units are only available to:

- (i) investors who have received advice from authorised intermediaries, platforms or other distributors in relation to their investment in units in the Trust; and
- (ii) distributors who the Manager reasonably considers will adequately bear the costs of marketing to and acquiring investors at no or limited cost to the Manager, and to whom the Manager has confirmed that such distributor or investor meets the criteria for investment in such units.

† With effect from 1 June 2018 – See Significant Changes on page 45.

Pricing and Dealing

The prices are published on the internet at www.legalandgeneral.com/investments/fund-information/daily-fund-prices immediately after they become available.

Dealing in units takes place on a forward pricing basis, from 8:30am to 6:00pm, Monday to Friday.

Buying and Selling Units

Units may be bought on any business day from the Manager or through a financial adviser by completing an application form or on the internet at www.legalandgeneral.com. Units may normally be sold back to the Manager on any business day at the bid price calculated at the following valuation point.

ISA Status

This Trust may be held within this tax advantaged savings arrangement. The favourable tax treatment of ISAs may not be maintained. For full written information, please contact your usual financial adviser or ring 0370 050 0955.

Call charges will vary. We may record and monitor calls.

General Information (unaudited) continued

Prospectus and Manager's Reports

The Manager will send to all persons on the Unitholder Register annual and interim short form reports.

Copies of the Prospectus and the most recent annual or interim reports are available free of charge by telephoning 0370 050 0955 or by writing to the Manager.

Do you have difficulty in reading information in print because of a disability? If so, we can help. We are able to produce information for our clients in large print and braille. If you would like to discuss your particular requirements, please contact us on 0370 050 0955.

Call charges will vary. We may record and monitor calls.

Information on Tracking Error

The 'Tracking Error' of a Trust is the measure of the volatility of the differences between the return of the Trust and the return of the benchmark Index. It provides an indication of how closely the Trust is tracking the performance of the benchmark Index after considering things such as Trust charges and taxation.

Using monthly returns, over the review year, the annualised Tracking Error of the Trust is 0.08%, whilst over the last three years to the end of December 2018, the annualised Tracking Error of the Trust is 0.07%. These Tracking Errors are within the anticipated Tracking Error levels set out in the Trust's Prospectus of +/-0.75% per annum.

Dual Pricing Arrangement

The Manager's fixed dual pricing arrangement has a set spread to account for the costs of transacting in a particular Trust. Where the Manager operates a box through which unit subscriptions and unit redemptions are netted into a single trade instruction to the Trustee, the netting reduces the actual transaction costs and this generates a revenue to the Manager. The revenue generated from this activity is calculated on a monthly basis and returned to the Trust in the form of a payment from the Manager. This provides an enhanced return to the Trust, though the size of any return will be dependent on the size of subscriptions and redemptions.

General Information (unaudited) continued

Remuneration Disclosure

In accordance with the Undertakings for collective investment in transferable securities (UCITs) Directive, often referred to as the UCITs V Directive, the Legal & General Global Health & Pharmaceuticals Index Trust, as a UCITs Scheme, is required to disclose the aggregate remuneration paid by the UCITs Manager and by the UCITs Scheme to Identified Staff, together with the number of beneficiaries, and, where relevant, performance fees paid by the UCITs Scheme. The aggregate amount of remuneration must be broken down by category of employees or other staff members and be split into fixed and variable remuneration.

The following provides information on the remuneration of persons whose professional activities have a material impact on the management company and the funds managed by it as at 31 December 2017. At the time of publishing, figures as at 31 December 2018 were not yet available. We shall publish this data in the Scheme's interim report, due to be published in September 2019.

Controlled Functions

Headcount	Fixed Remuneration (£,000)	Variable Remuneration (£,000)	Remuneration related to this Trust (Pro-rated) (£'000)
32	6,726	11,997	173

Market Risk Takers

Headcount	Fixed Remuneration (£,000)	Variable Remuneration (£,000)	Remuneration related to this Trust (Pro-rated) (£'000)
22	2,281	3,000	7

Controlled Functions

As at 31 December 2017, Legal & General Unit Trust Managers Limited (UTM) engaged the services of six employees of Legal & General Investment Management (Holdings) Limited (LGIMH), plus a further two employees of Legal & General Resources (LGR) to act as Directors. In addition there was one non-executive Director. UTM also engaged the services of a further 20 LGIMH employees and a further three L&G Resources (LGR) employees to act in a variety of Controlled Functions, including Chief Compliance Officer, Money Laundering Reporting Officer, Client Asset Oversight, Systems and Controls Functions, Significant Management Functions and Customer Functions. These employees were also engaged by other companies in the L&G Group. The aggregate remuneration received by these individuals, for all their services across the L&G Group, is disclosed in the table above. We have prorated the remuneration figures by the Net Asset Value of the UCITS Funds as a percentage of the total assets under management of UTM.

General Information (unaudited) continued

Material Risk Takers

As at the 31 December 2017, UTM engaged the services of Legal & General Investment Management's Index Fund Management team, which consists of 22 investment professionals located in our London Office. The team includes a variety of Fund Managers, Analysts and Support Staff, with the Fund Managers empowered to take discretionary investment management decisions on behalf of the Trust. The team is also engaged in managing other Legal & General UTM Funds/Schemes and is also engaged by other companies in the L&G Group. The aggregate remuneration received by the members of the team, for all their services across the L&G Group, is disclosed in the table above. We have prorated the remuneration figures by the Net Asset Value of the UCITS Funds as a percentage of the total assets under management of the Legal & General Investment Management's Index Fund Management team.

Significant Changes

Change in Fund Management Fee (FMF)

With effect from 1 June 2018, the FMF for R-Class units have been reduced from 0.95% to 0.69%.

Change of Auditor

With effect from 28 April 2018, PricewaterhouseCoopers LLP ceased to be Independent Auditors of the Trust and KPMG LLP have been appointed. The change of Auditor has no impact on the way the Trust is operated.

General Data Protection Regulation (GDPR)

Legal & General takes your privacy very seriously. Under data protection legislation, we have classified ourselves as a 'data controller'. This means that we are subject to certain obligations relating to how we process personal data. These obligations include, without limitation, providing individuals with certain information regarding how we process their personal data.

We will use the personal data you have provided to us in connection with an investment in units of Legal & General Global Health and Pharmaceuticals Index Trust, including your name, age, contact details, bank account details, transactions and the invested amount, and any information regarding the dealing in units in accordance with all applicable data protection laws and our Privacy Policy which is available from 25 May 2018 at www.lgim.com/UTMprivacy (or available upon request). Our Privacy Policy sets out, amongst other things, the purpose or purposes for which your personal data is collected and intended to be processed and also contains any other information prescribed by data protection legislation.

General Information (unaudited) continued

Authorised Fund Manager

Legal & General (Unit Trust Managers) Limited
Registered in England and Wales No. 01009418
Registered office:
One Coleman Street,
London EC2R 5AA
Telephone: 0370 050 3350
Authorised and regulated by the Financial Conduct Authority

Directors of the Manager

R. M. Bartley (resigned 31 December 2018)
A. J. C. Craven
S. Hynes
H. Morrissey
H. Solomon
S. D. Thomas (resigned 17 October 2018)
L. W. Toms
A. R. Toutouchi*
M. J. Zinkula

*Non-executive Director

Secretary

J. McCarthy

Registrar

Legal & General (Unit Trust Managers) Limited
P.O. Box 6080,
Wolverhampton WV1 9RB
Authorised and regulated by the Financial Conduct Authority

Dealing: 0370 050 0956
Enquiries: 0370 050 0955
Registration: 0370 050 0955

Call charges will vary. We may record and monitor calls.

Trustee

Northern Trust Global Services SE
Trustee and Depository Services
50 Bank Street,
Canary Wharf,
London E14 5NT

Authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority

Independent Auditors

KPMG LLP
15 Canada Square,
London E14 5GL

Investment Adviser

Legal & General Investment Management Limited
One Coleman Street,
London EC2R 5AA
Authorised and regulated by the Financial Conduct Authority

**Authorised and regulated by the
Financial Conduct Authority**

Legal & General
(Unit Trust Managers) Limited
Registered in England and Wales No. 01009418
Registered office:
One Coleman Street,
London EC2R 5AA
www.legalandgeneral.com

